← All candidates
30 insider filings on record.
30 filings on record.
MISTMilestone Pharmaceuticals Inc.
NasdaqGS · Healthcare · $149.40M
$1.20
-4.20% · Sep 16
30 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 12 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$149.40M
Float
106.5M
86% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
63.8
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
25 more transactions on Pro →Context
Wall St
$6.33 avg target
+427.8% vs today · 6 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.20 act−$0.39
Q4 '25−$0.15 act+$0.03
Q3 '25−$0.12 act+$0.05
Q2 '25−$0.20 act−$0.02
Coverage
Milestone (MIST) Q1 2026 Earnings TranscriptMotley Fool · 06-01Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To ProfitabilitySimply Wall St. · 05-15Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call SummaryMoby · 05-14Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...GuruFocus.com · 05-13
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice